Vasomedical Announces Application For Listing On The OTC Bulletin Board (“OTCBB”)

WESTBURY, N.Y.–(BUSINESS WIRE)–Vasomedical, Inc. (“Vasomedical”) (OTCQB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announced its engagement of a full service broker dealer to sponsor Vasomedical’s stock for quotation on the OTC Bulletin Board (“OTCBB”). The OTCBB is an electronic quotation system that displays real-time quotes, last-sales price, and volume information for many over-the-counter (“OTC”) securities that are not listed on the Nasdaq Stock Market or a national securities exchange.

Currently, the Company’s stock is quoted on OTC Link (previously, “Pink Sheets”) operated by OTC Markets Group, Inc. By listing onto the OTCBB, the company believes that its shareholders may potentially benefit by, among other things, additional exposure to the investment community, increased liquidity, and enhanced corporate image. The application is subject to acceptance by the Financial Industry Regulatory Authority (“FINRA”).

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP^® Therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

The Company reported an increase in revenue of $2.52 million, or 48.7%, to $7.70 million for the three months ended June 30, 2012, compared to revenue of $5.18 million for the same period in 2011. For the six months ended June 30, 2012, revenue was $13.74 million compared to $10.02 million for the six months ended June 30, 2011, an increase of 37.1%. The increase is the result of improved performance in all areas of our business, namely, sales of our EECP^® Therapy systems and sales from our China operations, as well as increased commission revenue for Vaso Diagnostics, Inc. We continue to record substantial amounts of deferred revenues, which will be recognized once the underlying equipment or service is accepted or performed. As of June 30, 2012, total deferred revenues were approximately $15.20 million, and the Company had cash and cash equivalents of approximately $11.78 million.

Net income for the three months ended June 30, 2012 was $54,000, compared to a net loss of $0.96 million for the same period in 2011. For the six months ended June 30, 2012 we had a net loss of $1.29 million compared to a net loss of $1.42 million for the same period in 2011. The improvement to profitability and the reduction in the loss reported for the three and six months ended June 30, 2012, respectively, compared to the same periods in 2011, was due to the increase in revenues for both our equipment operations and our sales representation business, offset by higher selling, general and administrative costs associated mainly with additional sales and marketing investments at our Vaso Diagnostics subsidiary, the addition of the China operations, and increased corporate expenses. Income attributable to common stockholders for the three months ended June 30, 2012 was $54,000 or $0.00 per common share, compared to a net loss of $1.11 million or $0.01 per common share for the three months ended June 30, 2011. For the six months ended June 30, 2012 we had a net loss attributable to common stockholders of $1.29 million or $0.01 per common share compared to a net loss applicable to common stockholders of $1.70 million or $0.01 per common share for the six months ended June 30, 2011.

“We are pleased that we are able to report a net income for the quarter ended June 30, 2012 and anticipate that we will continue to improve results in the second half of this year. Our equipment segment is beginning to show significant growth and we expect that this also will continue,” commented Dr. Jun Ma, President and Chief Executive Officer of the Company. “We will continue to pursue additional opportunities to expand our equipment segment and explore methods to grow our sales representation business,” Dr. Ma added.

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP^® Therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Summarized Financial Information

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

A veteran in the medical device industry, Mr. Hill was, until May 2011, interim Chief Executive Officer of Siemens Healthcare USA, the U.S. organization of the healthcare sector of Siemens AG (NYSE:SI), a German multinational conglomerate, where he was responsible for sales, marketing, service, and logistics across the Siemens Healthcare portfolio, including medical imaging equipment, healthcare information technology and medical therapy. For several years prior to that, Mr. Hill was Chief Operating Officer of Siemens Healthcare USA, responsible for setting and implementing national strategies to sell Siemens products and services, and achieving synchronization across Siemens Healthcare’s U.S. Business Management and Solutions Implementation teams. In addition to his career at Siemens Healthcare spanning several decades in a wide range of roles with many different responsibilities, Randy, as a recognized leader in the medical imaging business, is also former Chair of the Board of Medical Imaging & Technology Alliance (MITA), the leading organization and collective voice of medical imaging equipment manufacturers, innovators, and product developers, representing companies whose sales comprise more than 90 percent of the global market for medical imaging technology.

“Alternative sales channels are an effective sales strategy for any national or global manufacturer to achieve broad and sustainable success, and VasoHealthcare is a leading organization that has excelled in this field with a great performance track record,” commented Mr. Hill upon accepting the position. “I am very excited about joining the leadership at Vasomedical and leading an exceptional team of sales professionals at VasoHealthcare. I look forward to working with this young, energetic team towards growing the relationship with GE Healthcare to better serve our customers.”

Welcoming Mr. Hill to Vasomedical and VasoHealthcare, Dr. Jun Ma, President and CEO of Vasomedical, stated, “We are thrilled to have such a successful industry leader like Randy Hill as part of our leadership team. Randy’s in-depth knowledge of the diagnostic imaging business and broad understanding of the medical device industry will be an invaluable asset to VasoHealthcare and Vasomedical. I look forward to his advice in many aspects of our business and am confident that he will play a significant role in further development of our company to achieve its full potential.”

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP^® therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

The amendment, effective July 1, 2012, extends the initial term of three years commencing July 1, 2010 to five years through June 30, 2015, subject to earlier termination under certain circumstances. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GE Healthcare Diagnostic Imaging products to specific market segments in the 48 contiguous states of the United States and the District of Columbia.

“The extension of the agreement is verification of the professionalism, dedication and performance of our VasoHealthcare sales team” commented Jun Ma, President and CEO of Vasomedical, Inc. “The start of the sales representation business two years ago is part of the diversification strategy of the company, which also includes our expanded international operations and new product lines. We continue to look for accretive acquisitions as well as other related opportunities in the medical device business, with the objective of enhancing our business and increasing shareholder value.”

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP^® therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

The Company recorded revenue of $6.04 million for the three month period ended March 31, 2012, compared to revenue of $4.85 million for same period in 2011, an increase of 25%. The increase is primarily due to an increase of $925,000 in EECP^® and other medical equipment sales, or 175%, of which $578,000 was contributed by our recent acquisitions in China. Commission revenue at our wholly-owned subsidiary Vaso Diagnostics, Inc., d/b/a VasoHealthcare, also grew by $317,000, or 8%, for the three month period ended March 31, 2012. We continue to record substantial amounts of deferred revenues, which will be recognized once the underlying equipment or service is accepted or performed. As of March 31, 2012, total deferred revenues were approximately $14.78 million, a decrease of $0.45 million from December 31, 2011. At March 31, 2012, the Company had cash and cash equivalents of approximately $13.3 million.

Net loss for the three months ended March 31, 2012 was $1.34 million, compared to a net loss of $0.47 million for the same period in 2011. The increase in net loss was due to higher selling, general and administrative costs associated mainly with additional sales and marketing investments at our Vaso Diagnostics subsidiary, the addition of the China operations, and increased corporate expenses. Loss attributable to common stockholders was $1.34 million or $0.01 per common share for the three months ended March 31, 2012, compared to a net loss of $0.59 million or $0.01 per common share for the three months ended March 31, 2011.

“We are excited about the revenue growth in both segments but especially with the growth in our equipment segment,” commented Dr. Jun Ma, President and Chief Executive Officer of the Company. “We anticipate that our equipment segment will continue to grow and contribute significantly to our future success,” Dr. Ma continued. “We will continue to seek other opportunities to expand our equipment segment to further diversify our business and to enhance shareholder value.”

About Vasomedical

Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP^® therapy systems, its core product, as well as other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.

Summarized Financial Information

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.